MRC support for stratified medicine
The MRC’s Stratified Medicine Initiative began in 2010 and continues to be a major part of our research strategy, with a commitment of £65 million (see Figure 25) to fund a range of research consortia. A key priority of these research consortia is to strategically unite a wide range of expertise, from molecular biology and genomics to clinical care and the health care industry, along with the necessary infrastructure and patient cohorts. Bringing together all components of the research pipeline, from discovery science to translation by industry, will help accelerate our progress towards improving human health through patient sub-group targeted intervention.
In addition to the Stratified Medicine Initiative, the MRC has provided support to Molecular Pathology, an emerging discipline which seeks to define individual disease with a combination of DNA, RNA and/or protein-based diagnostic tests.
The additional commitments made under the Stratified Medicine Initiative and other awards addressing this research area have led to a year-on-year growth in expenditure over the past five years.